Search

Your search keyword '"Brufsky, Adam M"' showing total 242 results

Search Constraints

Start Over You searched for: Author "Brufsky, Adam M" Remove constraint Author: "Brufsky, Adam M" Database Unpaywall Remove constraint Database: Unpaywall
242 results on '"Brufsky, Adam M"'

Search Results

2. Supplementary Figure S1 from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

3. Data from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

4. Supplementary Table from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

5. Data from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

6. Supplementary Figure S2 from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

8. Biology of Coronaviruses and Predicted Origin of SARS-CoV-2

10. Effects of aerobic exercise on neurocognitive function in postmenopausal women receiving endocrine therapy for breast cancer: The Exercise Program in Cancer and Cognition randomized controlled trial

15. Erratum to Metaplastic Breast Carcinoma: A Clinical-Pathologic Study of 97 Cases With Subset Analysis of Response to Neoadjuvant Chemotherapy [Modern Pathology 32(6) (2019) 807–816]

16. Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer

17. Supplementary Tables 1-15 from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer

18. Supplementary Figures 1-7 from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer

19. Data from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer

20. Data from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer

21. Supplementary Figures 1-7 from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer

22. Supplementary Tables 1-15 from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer

23. Supplemental Table 1 from Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors

24. Supplementary Table 1 from Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER

25. Secondary Lymphedema Questionaire from Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment

26. Supplementary Figure 1 from Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment

27. Supplementary Figure 1 from Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment

28. Supplementary Figures 1-7 from Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence

29. Supplementary Data from Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs

30. Supplementary Figures 1-7 from Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence

31. Supplementary Figure 2 from Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment

32. Supplementary Figure 2 from Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment

33. Supplementary Table 1 from Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER

34. Supplementary Data from Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs

35. Supplementary Tables 1-2 from Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence

36. Supplementary Tables 1-2 from Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence

37. Secondary Lymphedema Questionaire from Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment

38. Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41

39. Abstract PD17-01: Genomic analysis of circulating tumor DNA (ctDNA) from patients with HR+, HER2-mutant metastatic breast cancer (MBC) enrolled in SUMMIT: mechanisms of acquired resistance to neratinib + fulvestrant + trastuzumab (N+F+T)

41. Abstract PD11-06: PD11-06 Circulating tumor DNA association with residual cancer burden after neoadjuvant therapy in triple negative breast cancer in TBCRC 030

42. Abstract OT2-01-07: evERA Breast Cancer: A phase III study of giredestrant (GDC-9545) + everolimus vs exemestane + everolimus in patients with estrogen receptor+, HER2– locally advanced or metastatic breast cancer

44. Abstract P4-02-20: Utility of the 70-gene signature and 10 year follow up in patients with early-stage breast cancer in a single institution study

45. Abstract PD9-08: ImPrint immune signature in 10,000 early-stage breast cancer patients from the real-world FLEX database

47. Abstract OT2-16-05: Safety Analyses of NRG BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-Positive Metastatic Breast Cancer (MBC)

49. Abstract PD7-03: Translational Breast Cancer Research Consortium Trial 022: Neratinib and Trastuzumab-Emtansine for HER2+ Breast Cancer Brain Metastases (BCBM)

Catalog

Books, media, physical & digital resources